P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement

Pharmacological Research

Volumn 48, Issue 4, 2003, Pages 347-359

  Varma, Manthena V S ^a   Ashokraj, Yasvanth ^a   Dey, Chinmoy S ^a   Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Inhibitors; Intestinal permeability; P glycoprotein; Peroral drug delivery; Pharmacokinetic optimization; Screening

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTIPARASITIC AGENT; BIRICODAR; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CYCLOSPORIN A; DEXVERAPAMIL; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOCAL ANESTHETIC AGENT; MULTIDRUG RESISTANCE PROTEIN; OC 144093; PACLITAXEL; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; QUINIDINE; RESERPINE; TARIQUIDAR; TOREMIFENE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; YOHIMBINE; ZOSUQUIDAR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DESIGN; DRUG ELIMINATION; DRUG METABOLISM; DRUG SCREENING; DRUG UPTAKE; HUMAN; INTESTINE ABSORPTION; ISOTOPE LABELING; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; TISSUE DISTRIBUTION;

EID: 0042167430     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00158-0     Document Type: Article

References (68)

1. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Del. Rev. 55:2003;3-29.
2. Juliano R.L., Ling L. A surface glycoprotein on modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 555:1976;152-162.
3. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular and pharmacological aspects of multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:1999;361-398.
4. Schinkel A.H., Kemp S., Dolle M., Rudenco G., Wagenaar E. N-Glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J. Biol. Chem. 268:1993;7474-7481.
5. Thiebut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I. Cellular localisation of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84:1987;7735-7738.
6. Higgings C.F., Gottesman M.M. Is the multidrug transporter a flippase? Trends Biochem. Sci. 17:1992;18-21.
7. Rosenberg MF, Kamis AB, Collaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 2003 (in press).
8. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
9. Sauna Z.E., Smith M.M., Muller M., Kerr K.M., Ambudkar S.V. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J. Bioenerg. Biomembr. 33:2001;481-491.
10. van Asperen J., Mayer U., van Tellingen O., Beijnen J.H. The functional role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci. 86:1997;881-884.
11. Shapiro A.B., Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem. Pharmacol. 53:1997;587-596.
12. Drori S., Eytan G.D., Assaraf Y.G. Potentiation of anticancer drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur. J. Biochem. 228:1995;1020-1029.
13. Eytan G.D., Regev R., Oren G., Assaraf Y.G. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J. Biol. Chem. 271:1996;12897-12902.
14. Doppenschmitt S., Spahn-Langguth H., Regardh C.G., Langguth P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 88:1999;1067-1072.
15. Hugger E.D., Novak B.L., Burton P.S., Audus K.L., Brochardt R.T. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J. Pharm. Sci. 91:2002;1991-2002.
16. Hugger E.D., Audus K.L., Brochardt R.T. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J. Pharm. Sci. 91:2002;1980-1990.
17. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1981;1967-1972.
18. Kerr D.J., Graham J., Cummings J., Morrison J.G., Thompson G.G., Brodie M.J.et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol. 18:1986;239-242.
19. Berg S.L., Tolcher A., O'Shaughnessy J.A., Denicoff A.M., Noone M., Ognibene F.P.et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J. Clin. Oncol. 13:1995;2039-2042.
20. Tolcher A.W., Cowan K.H., Solomon D., Ognibebe F., Goldspiel B., Chang R. Phase I crossover study of paclitaxel with R-verapamil in patients with metastatic breast cancer. J. Clin. Oncol. 14:1996;1173-1184.
21. Lum B.L., Kaubisch S., Yahanda A.M., Adler K.M., Jew L., Ehsan M.N.et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 10:1992;1635-1642.
22. Glisson B., Gupta R., Hodges P., Ross W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res. 46:1986;1939-1942.
23. Keller R.P., Altermatt H.J., Donatsch P., Zihlmann H., Laissue J.A., Hiastand P.C. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer. 51:1992;433-438.
24. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:1993;4595-4602.
25. Bardelmeijer H.A., Beijnen J.H., Brouwer K.R., Rosing H., Nooijen W.J., Schellens J.H.et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6:2000;4416-4421.
26. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M.et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56:1996;4171-4179.
27. Schellens J.H.M., Kruytzer M.F., Vasey P.A., Harris A.L.et al. Phase I and pharmacokinetics study of the P-glycoprotein inhibitor LY335979 and paclitaxel in patients with solid tumors. Am. Assoc. Cancer Res. 42:2001;535.
28. Stephens R.H., O'Neill C.A., Warhurst A., Carlson G.L., Rowland M., Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 296:2001;584-591.
29. Collett A., Higgs N.B., Sims E., Rowland M., Warhurst G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J. Pharmacol. Exp. Ther. 288:1999;171-178.
30. Stormer E., von Moltke L.L., Perloff M.D., Greenblatt D.J. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 19:2002;1038-1045.
31. Hammerle S.P., Rothen-Rutishauser B., Kramer S.D., Gunthert M., Wunderli-Allenspach H. P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. Eur. J. Pharm. Sci. 12:2000;69-77.
32. Tang F., Horie K., Borchardt R.T. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm. Res. 19:2002;765-772.
33. Tang F., Horie K., Borchardt R.T. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm. Res. 19:2002;773-779.
34. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
35. Schinkel A.H., Mol C.A., Wagenaar E., van Deemter L., Smit J.J., Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer. 31A:1995;1295-1298.
36. Umbenhauer D.R., Lankas G.R., Pippert T.R., Wise L.D., Cartwright M.E., Hall S.J., Beare C.M. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol. 146:1997;88-94.
37. Kwei G.Y., Alvaro R.F., Chen Q., Jenkins H.J., Hop C.E., Keohane C.A.et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos. 27:1999;581-587.
38. Hsing S., Gatmaitan Z., Arias I.M. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology. 102:1992;879-885.
39. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., Serabjit Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299:2001;620-628.
40. Sharom F.J., Yu X., Lu P., Liu R., Chu J.W., Szabo K.et al. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem. Pharmacol. 58:1999;571-586.
41. Scarborough G.A. Drug-stimulated ATPase activity of the human P-glycoprotein. J. Bioenerg. Biomembr. 27:1995;37-41.
42. Garrigues A., Nugier J., Orlowski S., Ezan E. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal. Biochem. 305:2002;106-114.
43. Urbatsch I.L., Sankaran B., Weber J., Senior A.E. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J. Biol. Chem. 270:1995;19383-19390.
44. Zakaria M., Brown P.R. High-performance liquid chromatography of nucleotides. J. Chromatogr. 226:1981;267-290.
45. Rebbeor J.F., Senior A.E. Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted form. Biochim. Biophys. Acta. 1369:1998;85-93.
46. Schmid D., Ecker G., Kopp S., Hitzler M., Chiba P. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem. Pharmacol. 58:1999;1447-1456.
47. Meyer S., Noisommit-Rizzi N., Reuss M., Neubauer P. Optimized analysis of intracellular adenosine and guanosine phosphates in Escherichia coli. Anal. Biochem. 271:1999;43-52.
48. Loe D.W., Sharom F.J. Interaction of multidrug-resistant Chinese hamster ovary cells with the peptide ionophore gramicidin D. Biochim. Biophys. Acta. 1190:1994;72-84.
49. Doppenschmitt S., Spahn-Langguth H., Regardh C.G., Langguth P. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter. Pharm. Res. 15:1998;1001-1006.
50. Hendrikse N., Vaalburg W. Dynamics of multidrug resistance: P-glycoprotein analyses with positron emission tomography. Methods. 27:2002;228.
51. Hunter J., Hirst B.H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral absorption. Adv. Drug Del. Rev. 25:1997;129-157.
52. Sababi M., Borga O., Hultkvist-Bengtsson U. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur. J. Pharm. Sci. 14:2001;21-27.
53. Erlichman C., Moore M., Thiessen J.J., Kerr I.G., Walker S., Goodman P.et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res. 53:1993;4837-4842.
54. Giaccone G., Linn S.C., Welink J., Catimel G., Stieltjes H., van der Vijgh W.J.et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. 3:1997;2005-2015.
55. Rowinsky E.K., Smith L., Wang Y.M., Chaturvedi P., Villalona M., Campbell E.et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 16:1998;2964-2976.
56. Kimura Y., Aoki J., Kohno M., Ooka H., Tsuruo T., Nakanishi O. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother. Pharmacol. 49:2002;322-328.
57. Callies S., de Alwis D.P., Wright J.G., Sandier A.et al. A population pharmacokinetic model for doxorubicin and doxorubucinol in the presence of a novel MDR modulator, Zosuquidar trihydrochloride (LY335979). Cancer Chemother. Pharmacol. 51:2003;107-118.
58. Guns E.S., Denyssevych T., Dixon R., Bally M.B., Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093, a new modulator of MDR in cancer chemotherapy. Eur. J. Drug Metab. Pharmacokinet. 27:2002;119-126.
59. van Zuylen L., Sparreboom A., van der Gaast A., Nooter K., Eskens F.A., Brouwer E.et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur. J. Cancer. 38:2002;1090-1099.
60. Ferry D., Price L., Atsmon J., Moshe I.et al. A phase IIA pharmacokinetic and pharmacodynamic study of the P-glycoprotein inhibitor, XR9576 in patients with doxorubicin chemotherapy. Proc. Am. Assoc. Cancer Res. 42:2001;950.
61. Smith C.D., Meyers C.B., Zilfou J.T., Smith S.N., Lawrence D.S. Indoloquinoxaline compounds that selectively antagonize P-glycoprotein. Oncol. Res. 12:2000;219-229.
62. Nerurkar M.M., Burton P.S., Borchardt R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13:1996;528-534.
63. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.T., Ambudkar S.V. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 37:1998;3594-3601.
64. Demeule M., Laplante A., Sepehr-Arae A., Beaulieu E., Averill-Bates D., Wenger R.M.et al. Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. Biochem. Cell Biol. 77:1999;47-58.
65. Hayashi M., Koike K., Rho M.C., Kuwano M., Kishiye T., Komiyama K. Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives. Anticancer Drug Res. 6:2001;255-260.
66. Zacherl J., Hamilton G., Thalhammer T., Riegler M., Cosentini E.P., Ellinger A.et al. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil. Cancer Chemother. Pharmacol. 34:1994;125-132.
67. Deferme S., van Gelder J., Augustijns P. Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an in-vitro screening. J. Pharm. Pharmacol. 54:2002;1213-1219.
68. Ferte J., Kuhnel J.M., Chapuis G., Rolland Y., Lewin G., Schwaller M.A. Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships. J. Med. Chem. 42:1999;478-489.